Scotiabank analyst Louise Chen raised the firm’s price target on Merck (MRK) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes the company’s execution was better than anticipated, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
- Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports
- Merck price target raised to $120 from $92 at Goldman Sachs
- Vaccine committee considers changes to childhood schedule, NY Times reports
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK